From 11 March....Change of CEO and Chief Scientist Interest Biomedical company, Tissue Therapies Limited (ASX: TIS) today announced that the CEO, Dr Steven Mercer has increased the shareholding of a related entity of which he is Trustee by another 46,500 shares in Tissue Therapies. These shares were bought on the open market and are reported in the attached Appendix 3Y. This brings the total Tissue Therapies shareholding of Dr Mercer’s related entity to 138,000 shares bought on the open market. The Chief Scientific Officer of Tissue Therapies, Professor Zee Upton and related entities have also recently increased their Tissue Therapies shareholding by open market purchases of an additional 74,000 shares, these purchases being completed on 28 February 2008. This brings the total shareholding of Professor Upton and related entities to 1,475,276 shares (4.76% of total issued equity). ENDS Further information: Dr Steven Mercer CEO, Tissue Therapies Limited Telephone: 07 3839 9938 Email: [email protected] About Tissue Therapies Limited Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue and various cell culture applications. The Company has worldwide exclusive rights to commercialise VitroGro®, a versatile growth factor based technology developed by tissue engineering experts at the Institute for Health and Biomedical Innovation at QUT for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, stem cell therapies and other cell culture uses. Based on its VitroGro® technology, Tissue Therapies is developing more effective medical treatments for wounds and burns, integration of orthopaedic and medical implants, and other applications such as cosmeceuticals. Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally. More information: www.tissuetherapies.com
TIS Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held